A new tyrosine hydroxylase genotype with orofacial dyskinaesia

Sultan Qaboos University Medical Journal

Volumn 14, Issue 3, 2014, Pages

  Al Muslamani, Ahood M ^a   Ali, Fouad ^a   Mahmood, Fatima ^a  

^a Department of Clinical Neurosciences ^*  (Bahrain)

Author keywords

Bahrain; Case Report; Dopa Responsive Dystonia; Tyrosine Hydroxylase

Indexed keywords

EID: 84904603166     PISSN: 2075051X     EISSN: 20750528     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Castaigne P, Rondot P, Ribadeau-Dumas JL, Saïd G. [Progressive extra-pyramidal disorder in 2 young brothers: Remarkable effects of treatment with L-dopa]. Rev Neurol (Paris) 1971; 124:162-6.
2. Willemsen MA, Verbeek MM, Kamsteeg EJ, de Rijk-van Andel JF, Aeby A, Blau N, et al. Tyrosine hydroxylase deficiency: A treatable disorder of brain catecholamine biosynthesis. Brain 2010; 133:1810-22. doi: 10.1093/brain/awq087.
3. Verbeek MM, Steenbergen-Spanjers GC, Willemsen MA, Hol FA, Smeitink J, Seeger J, et al. Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. Ann Neurol 2007; 62:422-6. doi: 10.1002/ana.21199.
4. Grattan-Smith PJ, Wevers RA, Steenbergen-Spanjers GC, Fung VS, Earl J, Wilcken B. Tyrosine hydroxylase deficiency: Clinical manifestations of catecholamine insufficiency in infancy. Mov Disord 2002; 17:354-9. doi: 10.1002/mds.10095.
5. Clot F, Grabli D, Cazeneuve C, Roze E, Castelnau P, Chabrol B, et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain 2009; 132:1753-63. doi: 10.1093/brain/awp084.
6. Nygaard TG, Snow BJ, Fahn S, Calne DB. Dopa-responsive dystonia: Clinical characteristics and definition. In: Segawa M, ed. Hereditary Progressive Dystonia with Marked Diurnal Fluctuation. New York, USA: Parthenon Publishing, 1993. Pp. 21-35.
7. Segawa M, Nomura Y. Hereditary progressive dystonia with marked diurnal fluctuation. In: Segawa M, ed. Hereditary Progressive Dystonia with Marked Diurnal Fluctuation. New York, USA: Parthenon Publishing, 1993. Pp. 3-19.
8. Furukawa Y, Guttman M, Kish SJ. Dopa-responsive dystonia. In: Frucht SJ, Fahn S, eds. Movement Disorder Emergencies: Diagnosis and Treatment. Totowa, New Jersey, USA: Humana Press, 2005. Pp. 209-29.
9. Casper C, Kalliolia E, Warner TT. Recent advances in the molecular pathogenesis of dystonia-plus syndromes and heredodegenerative dystonias. Curr Neuropharmacol 2013; 11:30-40. doi: 10.2174/157015913804999432.
10. Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJ, Gollamudi S, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007; 130:828-35. doi: 10.1093/brain/awl340.
11. Furukawa Y. Genetics and biochemistry of dopa-responsive dystonia: Significance of striatal tyrosine hydroxylase protein loss. Adv Neurol 2003; 91:401-10.
12. Hoffmann GF, Assmann B, Bräutigam C, Dionisi-Vici C, Häussler M, de Klerk JB, et al. Tyrosine hydroxylase deficiency causes progressive encephalopathy and dopa-nonresponsive dystonia. Ann Neurol 2003; 54:56-65. doi: 10.1002/ana.10632.
13. Furukawa Y. Update on dopa-responsive dystonia: Locus heterogeneity and biochemical features. Adv Neurol 2004; 94:127-38.
14. Leu-Semenescu S, Arnulf I, Decaix C, Moussa F, Clot F, Boniol C, et al. Sleep and rhythm consequences of a genetically induced loss of serotonin. Sleep 2010; 33:307-14.
15. Ribasés M, Serrano M, Fernández-Alvarez E, Pahisa S, Ormazabal A, García-Cazorla A, et al. A homozygous tyrosine hydroxylase gene promoter mutation in a patient with doparesponsive encephalopathy: Clinical, biochemical and genetic analysis. Mol Genet Metab 2007; 92:274-7. doi: 10.1016/j. ymgme.2007.07.004.
16. Lüdecke B, Knappskog PM, Clayton PT, Surtees RA, Clelland JD, Heales SJ, et al. Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet1996; 5:1023-8. doi: 10.1093/hmg/5.7.1023.
17. Wevers RA, de Rijk-van Andel JF, Bräutigam C, Geurtz B, van den Heuvel LP, Steenbergen-Spanjers GC, et al. A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC). J Inherit Metab Dis 1999; 22:364-73. doi: 10.1023/A:1005539803576.
18. De Lonlay P, Nassogne MC, van Gennip AH, van Cruchten AC, Billatte de Villemeur T, Cretz M, et al. Tyrosine hydroxylase deficiency unresponsive to L-dopa treatment with unusual clinical and biochemical presentation. J Inherit Metab Dis 2000; 23:819-25. doi: 10.1023/A:1026760602577.
19. de Rijk-Van Andel JF, Gabreëls FJ, Geurtz B, SteenbergenSpanjers GC, van Den Heuvel LP, Smeitink JA, et al. L-doparesponsive infantile hypokinetic rigid parkinsonism due to tyrosine hydroxylase deficiency. Neurology 2000; 55:1926-8. doi: 10.1212/WNL.55.12.1926.
20. Furukawa Y, Graf WD, Wong H, Shimadzu M, Kish SJ. Doparesponsive dystonia simulating spastic paraplegia due to tyrosine hydroxylase (TH) gene mutations. Neurology 2001; 56:260-3.